Biocon Gets US FDA Nod for Victoza Generic Diabetes Drug

Introduction to the FDA Approval

Biotechnology major Biocon Ltd announced on Thursday that its wholly-owned subsidiary, Biocon Pharma Ltd, has secured approval from the US Food and Drug Administration (US FDA). The approval is for its Abbreviated New Drug Application (ANDA) for Liraglutide Injection, a generic version of Victoza. The product will be available in 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens. This development marks a significant step for Biocon in expanding its portfolio of complex drug products for the US market.

Understanding Liraglutide and Its Market

Liraglutide is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise for treating insufficiently controlled Type 2 Diabetes Mellitus. It is approved for use in adults, adolescents, and children aged 10 years and above. This approval follows the company's earlier clearance for another Liraglutide injection, a generic version of Saxenda for chronic weight management, which it received on February 24, 2026. While the global Liraglutide market has seen a decline from its peak of nearly $1 billion in sales as patients migrate to newer therapies like semaglutide (Ozempic), it still represents a substantial opportunity, estimated at around $1 billion across the US and Europe.

Biocon's Strategic Position and Market Opportunity

Biocon's CEO and MD, Siddharth Mittal, highlighted that despite the market shift, a generic Liraglutide offers a crucial cost-effective alternative for patients and payers. The company anticipates healthy generic penetration due to limited competition in the US market. Biocon projects that its Liraglutide products could contribute between $10 million and $100 million in combined revenue from the US and Europe in fiscal year 2027. The company plans to launch the product commercially in the US within the next 30 to 45 days, prioritizing the American market rollout.

Strong Performance in European Markets

Biocon has already seen encouraging results from its Liraglutide launch in Europe. The company's generics segment reported a 24% year-on-year growth in the December quarter, with the majority of this growth attributed to Liraglutide sales in Europe. In specific tender-based markets like the Netherlands, Biocon and its partner Zentiva have already captured a significant market share of nearly 40%. This early success in Europe provides a strong foundation as the company prepares to enter the larger US market.

The Broader Competitive Landscape

The global GLP-1 market is becoming increasingly competitive, especially with the upcoming patent expiry of semaglutide in India around March 2026. Several major Indian pharmaceutical firms, including Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Lupin, are preparing to launch generic semaglutide products. This anticipated influx of generics is expected to intensify price competition. Biocon's strategy involves capitalizing on the near-term opportunity with Liraglutide, where competition is currently less fierce, while simultaneously preparing its pipeline for the semaglutide market. The company has started filing for semaglutide in emerging markets, with potential approvals expected by 2027.

Corporate Actions and Financial Health

To support its growth ambitions, Biocon has been strengthening its financial position and consolidating control over its subsidiaries. The company recently completed the acquisition of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) in two of its wholly-owned subsidiaries, Biocon Biosphere Ltd and Biocon Pharma Ltd. These investments, totaling over ₹315 crore, are aimed at funding working capital, capital expenditures, and other corporate needs.

These transactions, though involving related parties, are intended to streamline operations and support ongoing business requirements. Following these acquisitions, Biocon holds 100% of the paid-up share capital in both entities.

Future Outlook and Long-Term Strategy

Biocon's strategy is twofold: maximize the current opportunity with Liraglutide and prepare for the future of the GLP-1 market with semaglutide. The company's vertical integration, which covers everything from drug substance manufacturing to device integration, provides a significant competitive advantage in terms of cost efficiency and regulatory readiness. While acknowledging potential pricing pressure as innovator companies reduce costs for newer drugs, Biocon's management believes the limited competition for generic Liraglutide will help protect margins in the near term. The company's focus remains on exports and emerging markets, positioning it for sustained growth in the evolving global pharmaceutical landscape.

Conclusion

The US FDA's approval for generic Victoza is a key milestone for Biocon, reinforcing its capabilities in developing complex generic products. It allows the company to tap into the residual but still significant Liraglutide market with a competitive edge. By leveraging its strong performance in Europe and a clear strategy for both Liraglutide and the upcoming semaglutide wave, Biocon is positioning itself as a formidable player in the high-growth GLP-1 therapeutic area.